The U.S. Patent and Trademark Office Issuance Of An Additional Notice Of Allowance for Horizon Pharm

Horizon Pharma has announced receiving of a Notice of Allowance from the United States Patent and Trademark Office for U.S. patent application number 14/816,674 (U.S. publication number 2015-0335605), entitled “Methods of Therapeutic Monitoring of Nitrogen Scavenging Drugs”. The patent covers Horizon’s U.S. approved medicine RAVICTI® (Glycerol Phenylbutyrate) Oral Liquid. The notice states the substantive examination of the patent application and will only result in the issuance of a U.S. patent after completion of the administrative processes [more].